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Background: Outer membrane vesicles (OMVs) are spheroid particles released by all Gram-negative bacteria
as a result of the budding out of the outer membrane. Since they carry many of the bacterial surface-
associated proteins and feature a potent built-in adjuvanticity, OMVs are being utilized as vaccines, some of
which commercially available. Recently, methods for manipulating the protein content of OMVs have been
proposed, thus making OMVs a promising platform for recombinant, multivalent vaccines development.
Methods: Chlamydia muridarum DO serine protease HtrA, an antigen which stimulates strong humoral and
cellular responses in mice and humans, was expressed in Escherichia coli fused to the OmpA leader sequence
to deliver it to the OMV compartment. Purified OMVs carrying HtrA (CM rHtrA-OMV) were analyzed for
their capacity to induce antibodies capable of neutralizing Chlamydia infection of LLC-MK2 cells in vitro.
Results: CM rHtrA-OMV immunization in mice induced antibodies that neutralize Chlamydial invasion as
judged by an in vitro infectivity assay. This was remarkably different from what observed with an
enzymatically functional recombinant HtrA expressed in, and purified from the E. coli cytoplasm (CM
rHtrA). The difference in functionality between anti-CM rHtrA and anti-CM rHtrA-OMV antibodies was
associated to a different pattern of protein epitopes recognition. The epitope recognition profile of anti-CM
HtrA-OMV antibodies was similar to that induced in mice during Chlamydial infection.
Conclusions: When expressed in OMVs HtrA appears to assume a conformation similar to the native one and
this results in the elicitation of functional immune responses. These data further support the potentiality of
OMVs as vaccine platform.
Keywords: neutralizing antibodies; outer membrane vesicles; Chlamydia; DO serine protease; Chlamydia trachomatis
Received: 28 November 2012; Revised: 1 March 2013; Accepted: 12 March 2013; Published: 6 May 2013
O
uter membrane vesicles (OMVs) are closed spher-
oid particles of a heterogeneous size (10300 nm
in diameter) released from all Gram-negative
bacteria studied so far. Several experimental eviden-
ces indicate that OMVs are generated through a ‘‘bud-
ding out’’ of the bacterial outer membrane (OM) and,
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represented by lipopolysaccharide (LPS), glyceropho-
spholipids, OM proteins and periplasmic proteins (1).
It has been proposed that OMV release is an essential
step for bacteria to rapidly adapt to variations in the
external environment. These variations usually require
the expression of a number of surface-associated proteins
that have to replace the existing ones, and the release of
OMVs appears to be an efficient strategy to achieve OM
remodelling (2). However, a multitude of other functions
have been attributed to OMVs, including toxins and
virulence factors delivery to host cells, interspecies and
intraspecies cell-to-cell cross-talk, biofilm formation,
genetic transformation and defence against host immune
responses (2,3).
OMVs purified from several pathogens, includ-
ing Neisseria, Salmonella, Pseudomonas, Vibrio cholerae
Burkholderia and E. coli (48), induce potent protective
immune responses against the pathogens they are derived
from, and anti-Neisseria OMV-based vaccines are already
in the market and have shown to be very effective (9).
Such remarkable protection is attributed not only to the
presence of the correct immunogenic antigens but also
to the fact that OMVs carry most of the pathogen-
associated-molecular patterns (PAMPs) which play a
key role in stimulating innate immunity and promot-
ing adaptive immune responses. Because of this ‘‘built-in-
adjuvanticity’’ feature, several groups have reported
strategies to deliver heterologous proteins to OMVs,
with the ultimate objective to develop novel effective
vaccines (1014).
In this work, we provide an additional example of the
potentiality of OMVs as vaccine platform.
One of our research interests is the development of a
Chlamydia trachomatis vaccine. In this context, we have
recently applied reverse vaccinology and protein array
technologies to identify Chlamydia antigens which could
induce cell-mediated and humoral immune responses
(15). It is generally accepted that Chlamydia immunity
is mediated by both Chlamydia-specific Th1 CD4
 Tcells
and neutralizing antibodies (16). A 4 antigen combina-
tion was selected that provides robust protection in the
mouse model (15). One of the 4 selected antigens is the
DO serine protease HtrA, which is particularly unique in
that it induces both high antibody titres and IFNg
/
CD4
 T cells during natural infection in human beings
(Grifantini, personal communication) and during experi-
mental infection in mice. HtrA is a highly conserved
protein that belongs to the sophisticated and essential
system cells use to reduce the amount of unfolded
or aggregated proteins (17). In Gram-negative bacteria,
HtrA localizes in the periplasm, and it has been shown to
associate with phospholipids and cellular membranes
(18,19). As is the case for its E. coli homologue DegP
(17,19), Chlamydial HtrA assembles in an inactive trimer
which upon temperature induction forms high-molecu-
lar-weight 12- and 24-mer multimeric complexes with
proteolytic and chaperon-like activities (20,21). Further-
more, recent studies show that HtrA is released into the
cytosol of infected cells and suggest that the protein plays
a key role in Chlamydia pathology through a mechanism
that involves the proteolytic alteration of host cell
signalling pathways (22).
Here, we show that both C. muridarum (CM) HtrA
and C. trachomatis (CT) HtrA are exposed on the surface
of elementary bodies (EBs). Furthermore, we show that
CM HtrA expressed in E. coli with a leader sequence for
secretion is incorporated into OMVs. When CM rHtrA-
bearing OMVs (CM rHtrA-OMV) are used to immunize
mice, anti-HtrA-specific antibodies are induced that
neutralize Chlamydia infection as judged by an in vitro
infectivity assay. The neutralizing activity is not observed
with antibodies elicited by an enzymatically functional
recombinant HtrA (CM rHtrA) expressed in, and puri-
fied from, the E. coli cytoplasm. We also provide evidence
that the difference in functionality between anti-CM
rHtrA and anti-CM rHtrA-OMVantibodies is associated
with a different profile of protein epitope recognition.
To the best of the authors’ knowledge, this is the first
demonstration that, by virtue of their ability to carry
properly folded membrane-associated proteins, recombi-
nant OMVs can be exploited to induce functional im-
mune responses that otherwise would be difficult to elicit.
Altogether, these data reinforce the notion that OMVs
represent a promising platform for the development of
new effective vaccines.
Materials and methods
Bacterial strains, cultures and reagents
C. muridarum strain Nigg and CT serovar D strain D/
UW-3/CX were grown on confluent monolayers of LLC-
MK2 (ATCC CCL7) in Earle’s minimal essential medium
(EMEM) as described previously (23,24). Purification of
CT and CM EBs was carried out by renografin density
gradient centrifugation as described previously (23).
Escherichia coli BL21(DE3) was grown aerobically in
Luria broth (LB) medium (Difco) at 378C. When appro-
priate, ampicillin (Amp, 100 mg/mL), isopropyl-b-D-
galactopyranoside (IPTG; 1 mM) and kanamycin (Kana,
30 mg/mL) were added to the medium. Unless specified, all
chemicals used in this study were purchased from Sigma.
Restriction enzymes and DNA modification enzymes
were from New England Biolabs. Fluorescence-activated
cell sorter (FACS) reagents and antibodies were from BD
Biosciences.
Gene cloning and protein purification
To produce recombinant proteins CT and CM HtrA
(CT823 and TC0210), CT MOMP (CT681) and CM
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(PCR) amplified from CT and CM chromosomal DNA
using specific primers annealing at the 5’ and 3’ ends of
either gene and cloned into plasmid pET21b (Invitro-
gen), so as to fuse a 6-histidine tag sequence at the 3’ end.
Cloning and purification of His fusionswere performed as
already described (15,24). CT MOMP and CM MOMP
expressed as His fusion proteins were purified from the
insoluble protein fraction, while CT and CM rHtrA
expressed as His fusion proteins were purified from the
soluble protein fraction according to the manufacturer’s
procedure.
Construction of BL21(DE3) DtolR deletion mutant
The BL21(DE3) DtolR mutant was produced by replacing
tolR coding sequence with a kanamycin-resistance cas-
sette as described (25). Essentially, the tolR upstream and
downstream regions were fused to the kanamycin-resis-
tance gene (kmr) using a 3-step PCR protocol (25). The
linear fragment obtained, in which the kmr gene was
flanked by the tolR upstream and downstream regions,
was used to transform the recombination-prone BL21
(DE3) E. coli strain, and DtolR mutants were selected
by plating transformed bacteria on LuriaBertani (LB)
plates containing 30 mg/mL of kanamycin. Recombina-
tion-prone BL21 (DE3) cells were produced using the
highly proficient homologous recombination system
(red operon) (25,26). The deletion of the tolR gene was
confirmed by PCR amplification of genomic DNA using
pairs of primers specifically annealing to tolR and to kmr
gene, as described (25).
Expression of CM rHtrA in BL21(DE3) DtolR mutant
strain
In order to address CM rHtrA (TC0210) on the OM of
E. coli mutant strains, the CM htrA gene was amplified
with specific pairs of primers so as to replace the native
leader peptide with the E. coli OmpA leader peptide
(MKKTAIAIAVALAGFATVAQA) and to add a 6-
histidine tag sequence at the 3’ terminus. The PCR
product was inserted in pET21b (Invitrogen) plasmid
using the polymerase incomplete primer extension (PIPE)
cloning method (27) and the resulting plasmid was used
to transform E. coli HK100 cells, made CaCl2 competent
after several successive washes in cold MgCl2 and CaCl2
solutions (27).
Cells were plated on LB containing 100 mg/mL of
ampicillin (LB-Amp) at 378C overnight and positive
clones were selected by PCR analysis. Plasmid DNA was
isolated and used to transform BL21(DE3) DtolR strain,
made electro-competent by 3 washing steps in cold water.
The resulting BL21(DE3) DtolR(pET-htrA) strain was
grown in LB-Amp to an OD600 of 0.6 and induced with
1 mM IPTG for 2 h. C. muridarum rHtrA expression was
verified in total protein extracts and culture supernatant
of the BL21(DE3) DtolR(pET-htrA) strain by SDS-
PAGE and Western blot, using the BL21(DE3) DtolR
(pET) strain containing the empty pET21b vector as
the negative control.
OMV preparation and characterization
OMV preparation
Culture media of the BL21(DE3) DtolR(pET-htrA) and
BL21(DE3) DtolR(pET) strains were filtered through a
0.22-mm pore size filter (Millipore, Bedford, MA, USA).
The filtrates were clarified by centrifugation and sub-
jected to high-speed centrifugation (200,000g for 2 h),
and the pellets containing the OMVs were washed with
phosphate buffer saline (PBS) and finally resuspended
with PBS (25).
Laser-scattering analysis
Size distribution profile of OMVs was determined
by dynamic light scattering based on laser diffraction
method using Malvern Zetasizer (Version 6.0, Malvern,
UK). The OMV diameter was determined after dilution
in PBS (1/10) and by measuring the back scattering
intensity (1758)a t2 5 8C. Three measurements (15 experi-
mental runs for each measurement) were averaged to
determine the vesicle size.
Immunogold electron microscopy
Immunogold electron microscopy of OMV prepara-
tion was performed as previously described (25). Briefly,
purified OMVs were charged onto Formvar-coated nickel
grids, incubated for 10 min and incubated for 30 min in
PBS containing 1% bovine serum albumin (BSA) (block-
ing buffer). Samples were then labelled for 1 h with
polyclonal anti-CM rHtrA rabbit IgG, previously pre-
adsorbed on empty OMVs and diluted in blocking buffer
at a concentration of 10 mg/mL. After washing with block-
ing buffer, samples were subsequently incubated with a
1:40 dilution of a secondary goat anti-rabbit immunoglo-
bulin G conjugated to 5-nm gold particles (BB Interna-
tional). Finally, samples were washed and stainedwith 1%
(wt/vol) uranyl acetate in water before analysis in a TEM
FEI Tecnai G2 spirit operating at 100 kV and equipped
with a CCD camera (Olympus SIS Morada).
OMV protein digestion and mass spectrometry
analysis
OMV protein digestion was carried out using trypsin in
50 mM ammonium bicarbonate containing 0.1% (wt/vol)
RapiGest
TM SF Protein Solubilization Reagent (Waters)
and 5 mM dithiothreitol (DTT). The resulting peptides
were identified by LC/MS-MS. Peptides were separated
by nano-LC on a NanoAcquity UPLC system (Waters,
Milford, MA, USA) connected to a Q-ToF Premier ESI
mass spectrometer equipped with a nanospray source
(Waters). Samples were loaded onto a NanoAcquity
1.7-mm BEH130 C18 column (75 mm25 mm; Waters)
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column (180 mm20 mm; Waters). Peptides were eluted
with a 120-min gradient of 240% acetonitrile,
0.1% formic acid solution at a flow rate of 250 nL/min.
The eluted peptides were subjected to an automated
data-dependent acquisition using the MassLynx software,
version 4.1 (Waters) where an MS survey scan was used
to automatically select multicharged peptides over the
m/z ratio range 5002,000 for further tandem mass
spectrometry (MS/MS) fragmentation. Up to 8 different
peptides were individually subjected to MS/MS fragmen-
tation following each MS survey scan. After data ac-
quisition, individual MS/MS spectra were combined,
smoothed and centroided using ProteinLynx, version
3.5 (Waters) to obtain the peak list file. The Mascot
Daemon application (Matrix Science Ltd., London, UK)
was used for the automatic submission of data files to in-
house licensed Mascot, version 2.2.1, running on a local
server. Protein identification was carried out from the
generated peak list using the Mascot program (Mascot
server version 2.2.01, Matrix Science), using a public
database (National Center for Biotechnology Informa-
tion non-redundant (NCBInr), Gram-negative, release
June 19, 2007; 5,043,617 sequences) or a from database
containing protein sequences deduced from the available
sequenced E. coli BL21 genome. The Mascot search
parameters were set to (a) 2 as the number of allowed
missed cleavages (only for trypsin digestion); (b) methio-
nine oxidation and glutamine and asparagine deamida-
tion as variable modifications; (c) 0.3 Da as the peptide
tolerance; and (d) 0.3 Da as the MS/MS tolerance. Only
significant hits were considered as defined by the Mascot
scoring and probability system.
Protein localization was predicted using the software
LipoP (version 1.0; Center for Biological Sequence
Analysis, Technical University of Denmark (http://www.
cbs.dtu.dk/services/LipoP)) and Psortb (version 3.0.2;
Simon Fraser University, British Columbia (http://www.
psort.org/psortb)).
Preparation of anti-CM rHtrA and anti-CM rHtrA-OMV
antibodies
Mouse antisera were generated and treated as described
(24). Briefly, groups of 6-week-old female BALB/c mice
purchased from Charles River Laboratories (1015 mice/
group) were immunized intramuscularly (im) at 2-week
intervals with 3 doses (20 or 1 mg) of purified CM rHtrA
or 50 mg of CM rHtrA-OMV formulated with alum hy-
droxide as an adjuvant at the final concentration of 3 mg/
mL. Groups of mice that received the adjuvant alone or
‘‘empty’’ OMVs not expressing HtrAwere included as the
negative control. Immune sera were prepared from blood
samples collected on day 60 and pooled before use.
Rabbit anti-CM rHtrA IgGs were obtained as follows:
2 female New Zealand rabbits (approximately 2 kg) were
immunized subcutaneously at days 1, 20 and 35 with
3 doses (100 mg) of CM rHtrA formulated with equal
volumes of Freund’s adjuvant. Two weeks after the last
immunization rabbits were bled, sera pooled and the total
IgGs were purified by affinity chromatography on Protein
A Sepharose Fast Flow (GE Healthcare) following the
manufacturer’s instructions. All procedures were ap-
proved by the National Health Institution and Novartis
Vaccines Animal Care and Ethical Committee. Unless
otherwise specified, before immunological analysis im-
mune sera were incubated overnight at 48C with nitro-
cellulose strips adsorbed with an E. coli BL21 total
protein extract (E. coli contaminants), in order to reduce
the amount of antibodies elicited by contaminating E.
coli antigens.
Enzyme-linked immunosorbent assay
Serum IgG titres directed to CM rHtrA were assayed by
enzyme-linked immunosorbent assay (ELISA). Indivi-
dual wells of micro-ELISA plates (Nunc Maxisorp) were
coated with 1 mg of CM rHtrA in PBS (pH 7.4) at 48C
overnight. The plates were washed, treated for 1 h at 378C
with PBS1% BSA, and 100 mL aliquots of antisera
at different serial dilutions in PBS0.1% Tween 20 were
added to the wells. After incubation for 2 h at 378C,
plates were again washed and incubated for 1 h at 378C
with alkaline phosphatase-conjugated goat anti-mouse
IgG (Sigma) diluted at 1:2,500 in PBSTween 20. Later,
100 mL of PNPP substrate (Sigma) was added to the
samples and incubated for 30 min at room temperature
and optical densities (ODs) were read at 405 nm. Serum
antibody titreswere defined as the reciprocal of the serum
dilution yielding an OD value of 0.5.
Western blot assay
For Western blot analysis, total proteins from purified
EBs of CM strain Nigg or CT serovar D strain D/UW-3/
CX (2 mg/lane), or OMV preparations or purified rHtrA
(20 mg and 200 ng, respectively, unless otherwise stated)
were respectively separated by SDS-PAGE (412% gel)
under reducing conditions and electroblotted onto nitro-
cellulose membranes. After saturation with PBS0.1%
Tween 20 containing 5% skim milk, the membranes were
incubatedwith the indicated sera diluted at 1:200 in PBS
0.1% Tween 203% skim milk (antibody buffer) for 2 h
at 378C. After washing with the antibody buffer, mem-
branes were incubated with a peroxidase-conjugated anti-
mouse antibody (diluted at 1:3,000 in the antibody
buffer) for 1 h at 378C. After washing with PBS0.1%
Tween 20, blots were developed using an Opti-4CN
Substrate Kit (Bio-Rad). The densitometric analysis of
CM rHtrA bands was done with the ImageJ software
(National Institutes of Health).
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Flow cytometry analysis on CT and CM was performed
as described previously (24). Purified CM or CT EBs
were rendered not infectious by UV treatments. Inacti-
vated EBs (210
5 cells) resuspended in PBS0.1% BSA
were incubated for 30 min at 48C with anti-CM rHtrA
and anti-CM rHtrA-OMVantibodies, using anti-rMOMP
antibodies as positive controls (standard dilution: 1:200).
As the negative control, anti-CM rHtrA and anti-CM
rHtrA-OMV antibodies were also tested on E.coli
expressing CM rHtrA in the intracellular compartment.
After centrifugation and washing with PBS0.1% BSA,
the samples were incubated for 30 min at 48C with goat
anti-mouse IgG, F(ab)’2-specific, conjugated with R-
Phycoerythrin (Jackson Immunoresearch Laboratories
Inc.). The samples were washed and resuspended in
PBS0.1% BSA and analyzed by a flow cytometer.
For flow cytometry analysis of OMVs, CM rHtrA-
OMV and ‘‘empty’’ OMV preparations were incubated
for 30 min at 48C with affinity-purified rabbit anti-CM
rHtrA IgG (dilution: 1/100) or with irrelevant purified
rabbit IgG and subsequently incubated with an Alexa
Fluor 647† fluorescently labelled goat anti-rabbit anti-
body (dilution: 1/800), without washing steps. Additional
controls included OMV staining with the secondary
antibody alone. Flow cytometry data were acquired on
a FACS Canto
TM II (BD Biosciences). The settings for
acquisition of the samples used detector amplifications
not exceeding 370 V to avoid the light laser’s noise and
adjusting the threshold in order to decrease the noise
background. Samples were acquired using the Cell Quest
Software (Becton Dickinson, Mountain View, CA, USA)
and analyzed using FloJo software v9.1 (Tree Star Inc.).
Data significance was elaborated by calculating the
KolmogorovSmirnov statistics (KS score) (28).
In vitro serum neutralization assays
CT and CM neutralisation assays were performed in
LLC-MK2 (rhesus monkey kidney) epithelial cell cul-
tures as previously described (24). Briefly, 15 mLo fC T
EBs or CM EB suspension (310
5 IFU/mL diluted in
sucrose phosphate buffer (SP)) were added to serial
dilutions of pre-immune and immune sera from vacci-
nated mice and incubated for 30 min at 378C on a slowly
rocking platform, also including EB samples without
serum as the infection control (EBsSP control). One
hundred microlitres of each dilution was then inoculated
in duplicate into LLC-MK2 confluent monolayers in a
96-well plate and centrifuged at 750 g for 1 h at 378C.
After centrifugation, EMEM containing 10% foetal
bovine serum and 1 mg/mL cycloheximide were added.
Infected cultures were incubated at 378C for 48 or 24 h
for CT and CM, respectively. After methanol fixation,
monolayers were stained with a mouse anti-Chlamydia
fluorescein-conjugated monoclonal antibody (Merifluor
Chlamydia, Meridian Diagnostics, Inc.) and counted for
IFUs.
The reduction of infectivity due to EB interaction with
the immune sera was calculated as the percentage reduc-
tion in mean IFU number as compared to the EBsSP
control. In this calculation, the IFU counts obtained with
immune sera were further corrected for background
inhibition of infection of the corresponding pre-immune
mouse serum. Experimental variability was evaluated by
calculating the standard error of measurement (SEM),
from3titrationexperimentsforeachrecombinantantigen.
Peptide spot synthesis
Spot synthesis of 15-mer peptides, overlapping by 10,
and covering the mature form of the CM HtrA sequence
was performed on 3 amino-polyethyleneglycol-cellulose
membranes by an automated spot synthesizer (Multi-
SynTech, Bochum, Germany) using 9-fluorenylmethox-
ycarbonyl chemistry and O-(benzotriazol-1-yl)-N,N,N,
N-tetramethyluronium hexafluorophosphate-1,3-diiso-
propylethylamine activation. After the final synthesis
cycle, the side-chain protective groups were removed us-
ing a mixture of trifluoroacetic acidtriisobutylsilane
waterdichloromethane.
Peptide binding assay
Cellulose-bound peptides were soaked in ethanol to
prevent hydrophobic interaction between the peptides.
Non-specific binding was blocked by incubating cellulose
membranes overnight at 48C with 10 mL of 5% skim milk
in PBS containing 0.05% Tween 20. The membranes were
incubated with anti-CM rHtrA and anti-CM rHtrA-
OMV antibodies and with sera from mice that received 2
sequential infections with CM EBs, for 2 h at 378C (1/200
dilutions). After washing, membranes were incubated
with an HRP-conjugated goat anti-mouse immunoglo-
bulin G (1/1,000 dilution) and developed with Opti 4CN-
substrate kit (BIORAD). The analysis was repeated twice
with identical results. The staining of the empty OMV
antiserum and the secondary antibody on the same panel
of peptides was negligible.
Molecular modelling
The crystal structures of E. coli DegP (PDB IDs: 1ky9,
2zle and 3cs0) were used to generate homology models of
CM rHtrA. Models were generated using Modeller9v8.
Graphical representation shown in Fig. 5C were gener-
ated with UCSF Chimera 1.5.1.
Results
Antibodies against recombinant HtrA recognize HtrA
on the EB surface but do not neutralize Chlamydia
infectivity in vitro
One immunological mechanism that can contribute to
Chlamydia immunity is the elicitation of antibodies which
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induce such antibody-mediated neutralizing activity is its
exposure on the EB surface. We previously demonstrated
that HtrA is present on the surface of Chlamydia
pneumoniae EBs (24). Therefore, to establish whether EB
surface expression is a general feature in all Chlamydia
species, thus making HtrA a possible target for neutraliz-
ing antibodies, we scanned the surface of both CT and
CM EBs using flow cytometry and MS analyses.
Polyclonal antibodies raised against recombinant CM
HtrA (CM rHtrA) and CT HtrA (CT rHtrA) purified
from the E. coli cytoplasm were tested for their ability to
bind EBs by flow cytometry. As shown in Fig. 1A, both
anti-CM rHtrA and anti-CT rHtrA antibodies stained
the surface of whole EB populations, giving a shift in the
mean fluorescence peak of approximately 0.7 log with
respect to the negative control serum. The same anti-
bodies did not bind the surface of E.coli expressing CM
rHtrA in the cytoplasm, further confirming the specificity
of the EB surface immune-staining (Fig. 1S). HtrA
surface localization was also verified by subjecting CT
EBs to mild trypsin digestion, so as to remove the protein
domains protruding out of the EB surface while preser-
ving EB integrity (29). After digestion, ‘‘shaved’’ EBswere
removed by filtration and the proteolytic peptides present
in the supernatant were analyzed by MS/MS. The peptide
mixture included one specific peptide matching the
sequence GENVLLMVSQGDVVR and corresponding
to the HtrA region from amino acid 475489 located at
the carboxy-terminus of the protein.
We next assessed the ability of anti-rHtrA antibodies to
prevent EB infection of LLC-MK2 cells in vitro. CT and
CM EBswere pre-incubatedwith anti-CTrHtrA and anti-
CM rHtrA antibodies, respectively, and then used to in-
fect LLC-MK2 cell monolayers. Inclusions were counted
under the microscope after 48- or 24-h-incubation for CT
and CM, respectively. Sera against recombinant MOMP
of CTand CM (anti-CTrMOMP and anti-CM rMOMP)
were used as positive controls of the invitro neutralisation
assay (30,31). While antibodies against rMOMP were able
to neutralize EB infectivity invitro, anti-rHtrA antibodies
only weakly inhibited inclusion formation in LLC-MK2
cells (Fig. 1B) and the IFU reduction did not reach 50%,
the threshold value usually used to score a serum as
neutralizing. Neutralization ability of anti-rHtrA anti-
bodies was not improved by formulating the protein with
different adjuvants, including Freund, alum or LTK63-
CpG (data not shown).
We tested whether the inability to induce neutraliz-
ing antibodies was due to structural modification of the
protein which, when expressed in the E. coli cytoplasm,
did not assemble in proteolytically active multimers. For
this purpose, purified CM rHtrA was subjected to an in
vitro protease assay, using BSA as the substrate. The
results of this analysis indicated that the protein could
almost completely hydrolyse the substrate after 16-h
incubation at 378C (Fig. 2S).
Overall, these results indicate that HtrA expressed in
the E. coli cytoplasm forms high-molecular-weight com-
plexes and is proteolytically active but is unable to elicit
neutralizing antibodies in mice.
Fig. 1. Surface-exposed Chlamydia HtrA does not elicit neutra-
lizing antibodies. (A) HtrA Chlamydia HtrA is expressed on the
EB surface. Puriﬁed CM (left panel) and CT (right panel) EBs
were incubated with sera raised against CM rHtrA or CTrHtrA
(empty peaks) or anti-E. coli contaminants (shaded peaks)
and the antibody binding on EB surface was detected by ﬂow
cytometry using a R-Phycoerythrin-conjugated secondary anti-
body. Inset panels: Western blot analysis of HtrA expressed
by EBs. Total extracts from CM or CT EBs (approximately 10
7)
and puriﬁed CM or CT rHtrA were separated on SDS-PAGE,
transferred to nitrocellulose membranes and incubated with the
correspondingrHtrA antiserum. Molecular weightstandardsare
reported on the left side of each panel. (B) Antibodies elicited by
CM rHtrA do not neutralize Chlamydia infectivity invitro. Anti-
CM rHtrA and anti-CTrHtrA antibodies were pre-incubated at
different dilutions with infectious CM EBs (left panel) and CT
EBs (right panel), respectively, and used to infect LLC-MK2 cell
monolayers, as compared with EBs treated with corresponding
dilutions of pre-immune sera. As positive controls, anti-CM
rMOMP and anti-CT rMOMP were also used simultaneously.
The antiserum neutralization activity was determined by mea-
suring the reduction of the number of inclusions generated by
antibody-opsonized EBs after correction for background inhibi-
tion observed with pre-immune sera. The graphs represent the
percent neutralization averaged from triplicate experiments, with
standard deviations.
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expressed fused to the OmpA signal sequence
We next investigated whether by delivering CM HtrA to
the periplasmic space of E. coli, the protein could be
incorporated into OMVs. We were also interested to
know whether the protein, similarly to what happens in
chlamydial EBs, could reach the E. coli OM and therefore
be detected on the surface of OMVs.
Hence, using the IPTG-inducible expression plasmid
pET21, CM rHtrA was expressed fused to the OmpA
leader sequence in BL21(DE3) DtolR,a nE. coli mutant
strain shown to release large quantities of OMVs into the
culture supernatant. BL21(DE3) DtolR(pET-htrA) was
grown at 0.6OD600 and then HtrA expression was induced
with 1 mM IPTG (Fig. 3S). After 2-h induction, OMVs
were purified from the bacterial culture supernatant by
ultracentrifugation and their quality was assessed by light
scattering and electron microscopy (EM) to establish the
size and homogeneityof OMVs, and by proteome analysis
to confirm that most of the OMV proteins belonged to the
OM and periplasmic compartment. Malvern Zetasizer
and EM analyses indicated that the majority of the
vesicles was in the 2550 nm range, similar to the size of
OMVs purified from BL21(DE3) DtolR(pET) as the
control (Fig. 4S).
In the case of proteomic analysis, OMVs purified from
BL21(DE3) DtolR(pET-htrA) strain were digested with
trypsin and the proteolytic peptides were then analyzed
by LC/MS-MS. A total of 29 proteins were identified in
the CM rHtrA-OMV preparation, 15 of which were also
identified in OMVs of the recipient strain BL21(DE3)
DtolR(pET) (referred as ‘‘empty’’ OMVs). According
to the software LipoP (http://www.cbs.dtu.dk/service/
LipoP) and Psortb (http://www.psort.org/psortb), of the
29 identified proteins, 26 (89.7%) could be classified
either as lipoproteins, OM or periplasmic proteins, while
the remaining 3 proteins are predicted as cytoplasmic or
have unknown localization (Table IS).
Next, we estimated the presence of CM rHtrA in
OMVs. The first demonstration that delivery of CM
rHtrA to the periplasm of E. coli results in the incorpora-
tion of rHtrA in OMVs derived from MS analysis
described above. As shown in Table IS, CM rHtrA was
detected in the CM rHtrA-OMV preparation, while not in
the OMVs from the recipient strain.
Furthermore, CM rHtrA compartmentalization was
investigated by Western blot analysis. After cell separa-
tion, 500 mL of culture supernatant were ultracentri-
fuged, the OMV pellet was resuspended in 500 mL of PBS
and 5 mL were loaded on SDS-PAGE. Five millilitres of
the culture supernatant and of the ultracentrifugation
supernatant were TCA-precipitated and loaded simulta-
neously. As shown in Fig. 2A, CM rHtrA was found in
the culture supernatant and the majority of it accumu-
lated in the OMV fraction.
Finally, CM rHtrA quantification was carried out
by densitometric analysis of immunoblot. Particularly,
different doses of CM rHtrA-OMVs were subjected
to Western blot and the intensity of the HtrA band of
approximately 48 kDa (Fig. 2B) was compared with the
corresponding band of defined amounts of CM rHtrA.
This analysis indicated that in 12.5 mg of CM rHtrA-
OMVs, approximately 20 ng of CM rHtrA were present
corresponding to 0.16% of the total OMV proteins.
To address whether CM rHtrA is found on the surface
of the vesicles, we used flow cytometry and EM analyses.
In the case of flow cytometry analysis, CM rHtrA-OMVs
were incubated with anti-CM rHtrA antibodies followed
by staining with fluorescence-labelled secondary antibo-
dies. Upon antibody treatment, a consistent shift in the
fluorescent intensity of OMVs was observed (Fig. 2C and
5S). OMV localization of CM rHtrAwas also analyzed by
immune electron microscopy using gold-labelled second-
ary antibodies. As shown in Fig. 2D, approximately 33%
of OMVs (based on analysis of 7 EM fields containing 205
OMVs) were found associated with gold particles. This is
consistent with thefact that since OMVs areconstitutively
released throughout bacterial growth, only OMVs gener-
ated after IPTG induction should be loaded with
HtrA. Interestingly, similar to what Shen and colleagues
(32) observed recently, the gold particles appeared to be
confined in electron-dense protein material, which ad-
hered to the surface of OMVs (Fig. 2D). A significant
fraction of the gold particles were either not in direct
contact with OMVs or were freely dispersed in the EM
field (approximately 75% of all counted gold particles).
While this might partly be due to a partial OMV rupture
during sample preparation, the nature of HtrA interac-
tion with OMVs deserves further investigation.
From these analyses, we concluded that delivering
CM rHtrA to the E. coli periplasm allows its association
with the OMVs and that the protein is at least partially
exposed on the surface of OMVs.
CM rHtrA-OMV induces anti-HtrA-specific
antibodies in mice
We next analyzedwhether CM rHtrA-OMV could induce
HtrA-specific antibodies in mice. BALB/c mice (6 mice/
group) were immunized with 3 doses (given at 2-week
intervals) of 50 mg of CM rHtrA-OMV (total protein
content) formulated in alum hydroxide, and anti-HtrA
antibody titreswere comparedwith titres elicited by 1 and
20 mg of CM rHtrA (3 doses in alum hydroxide).
As shown in Fig. 3A, CM rHtrA-OMV induced anti-
HtrA-specific antibodies at titres that were only 3-fold
lower than those obtained upon immunization with 1 mg
of alum-formulated CM rHtrA, even though the amount
of HtrA present in 50 mg of CM rHtrA-OMVs was
estimated to be approximately 0.1 mg. This piece of data
suggests that OMVs exert an adjuvant effect on rHtrA
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ticity on rHtrA also occurred by adding 50 mg of ‘‘empty’’
OMVs to 1 mg of alum-formulated CM rHtrA. As shown
in Fig. 3A, this was not the case in that empty OMVs
addition appeared to decrease rather than increase in
HtrA-specific antibody titres. The highest antibody titres
were obtained by immunizing animals 3 times with 20 mg
of alum-adjuvanted CM rHtrA (Fig. 3A). Finally, no
anti-CM HtrA antibodies were detected when mice
were immunized with ‘‘empty’’, alum-formulated, OMVs
derived from BL21(DE3) DtolR(pET), indicating that the
endogenous E. coli HtrA (approximately 43% identity
with CM-HtrA) did not induce antibodies cross-reacting
with CM HtrA.
The specificity of anti-HtrA antibodies elicited by CM
rHtrA-OMV immunization was further confirmed by
Western blot analysis on total extracts from renografin-
purified CM EBs (approximately 10
7 EBs/lane). As
shown in Fig. 3B, sera from mice immunized with
50 mg of CM rHtrA-OMV were able to detect HtrA
Fig. 2. CM rHtrA expressed by E. coli BL21(DE3) DtolR(pET-htrA) is associated with the OMV fraction and is partially detected on
the OMV surface. (A) Western blot analysis of CM rHtrA expression and compartmentalisation. Mid log cultures of E. coli BL21(DE3)
DtolR(pET-htrA) (marked as DtolR(pET-htrA)) were induced with 1 mM IPTG for 3 h. CM rHtrA expression was assessed by Western
blot in total bacterial extracts (TE), culture supernatant before (S1) and after (S2) OMV puriﬁcation and in the puriﬁed OMV fraction.
Each loaded sample corresponded to 5 mL of the original bacterial culture. OMVs puriﬁed from the recipient strain E. coli BL21(DE3)
DtolR(pET) (empty OMV) and IMAC-puriﬁed CM rHtrA were run simultaneously as controls. As shown in the ﬁgure, CM rHtrA
exists in 2 major protein species of approximately 48 and 20 kDa, representing the full length and a processed form of the protein, as
veriﬁed by MALDI-TOF analysis. Both bands are also visible in the DtolR(pET-htrA)-derived samples. CM rHtrA bands show a
slightly higher molecular weight due to the presence of the histidine tag. Molecular weight markers are on the left. (B) Estimation of
CM rHtrA amount present in CM rHtrA-OMVs by comparative Western blot. Different quantities of CM rHtrA-OMVs and CM
rHtrA were analyzed by immunoblot and the amount of rHtrA present on CM rHtrA-OMVs was estimated by densitometric analysis
of the 48-kDa HtrA band (boxed). (C) FACS analysis of rHtrA surface exposure on CM rHtrA-OMV. Puriﬁed CM rHtrA-OMV
(empty peak) and ‘‘empty’’ OMVs (shaded peak) were incubated with anti-CM rHtrA antibodies. CM rHtrA-OMV were also
incubated with antibodies raised against E. coli contaminants (dotted peak) as an additional negative control. The binding was revealed
using an Alexa Fluor 647 labelled secondary antibody. (D) Immuno electron microscopy analysis of CM rHtrA-OMV. CM rHtrA-
OMVs and empty OMVs were incubated with anti-CM rHtrA antibodies and the presence of rHtrA was detected with a secondary
gold-conjugated antibody. Arrows indicate HtrA immunogold staining. Bars represent the image size scale.
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OMVs did not.
Finally, we analyzed the ability of anti-CM rHtrA-
OMVantibodies to bind to the surface of chlamydial EBs
by flow cytometry. As shown in Fig. 3C, the antibodies
gave a shift in fluorescence intensity comparable to the
one obtained using anti-CM rHtrA antibodies, whereas
sera against ‘‘empty’’ OMVs were negative.
Anti-CM rHtrA-OMV antibodies neutralize
Chlamydia infectivity in vitro
With the experiments described above, we demonstrated
that CM rHtrA-OMVs induced HtrA-specific antibodies.
We next analyzed whether, in contrast to what was
observed with anti-CM rHtrA antibodies, the antibodies
induced by CM rHtrA-OMV could neutralize Chlamydia
infectivity in vitro. Hence, we repeated the same in vitro
neutralization assay described above by pre-incubat-
ing CM EBs with anti-CM rHtrA-OMV mouse sera.
As shown in Fig. 4 (left panel), CM EB infection was
significantly reduced and neutralisation titres were simi-
lar to those obtained with anti-CM rMOMP polyclonal
antibodies used as a positive control. Anti-CM rHtrA-
OMV antibodies were also able to cross-neutralize the
infectivity of CT EBs, while anti-CM rMOMP antibo-
dies, as expected for a protein which is species-specific,
did not show any cross-neutralisation (Fig. 4, right
panel).
One possible explanation of the functional difference
between anti-CM rHtrA-OMV and anti-CM rHtrA
antibodies is that the strong adjuvant effect of OMV
might influence not only the quantity but also the quality
of antibody response. However, immunization with rHtrA
mixed with empty OMV in alum did not increase the
neutralizing activity of the sera with respect to immuni-
zation with rHtrA alone (data not shown). A second
interpretation is that anti-CM rHtrA-OMV and anti-CM
rHtrA antibodies recognize different protein epitopes. To
investigate this hypothesis, an epitope mapping analysis
was carried out using anti-CM rHtrA-OMV and anti-
Fig. 3. Antibodies raised against rHtrA-OMV recognize C.
muridarum HtrA and bind the EB surface. (A) HtrA-speciﬁc
ELISA IgG titres. Sera from mice immunized with different
OMV formulations (CM rHtrA-OMV, empty OMV and empty
OMV mixed with rHtrA) and with puriﬁed rHtrA (doses of 20
and 1 mg) were collected 2 weeks after the third immunization
and IgG titres were analyzed by ELISA. Bars represent the
mean titres of each mouse group expressed as the reciprocal of
the serum dilution yielding an OD value of 0.5. (B) Western blot
analysis of CM EBs. Total extracts of CM EBs and puriﬁed CM
rHtrA were loaded on the gel, transferred to nitrocellulose and
immunoblots were probed using antibodies raised against CM
rHtrA-OMV (left panel) and empty OMV (right panel).
Molecular weight standards are reported on the left of each
panel. (C) Flow cytometry analysis of CM EBs. CM EBs were
incubated with anti-CM rHtrA-OMV (open peak) and anti-
empty OMV antibodies (shaded peak) and surface-bound
antibodies were detected by ﬂow cytometer using a R-phycoer-
ythrin-conjugated secondary antibody.
Fig. 4. Antibodies directed against CM rHtrA-OMV neutralize
Chlamydia infectivity in vitro. CM EBs (left panel) and CT EBs
(right panel) were opsonized with sera directed against CM
rHtrA, CM rHtrA-OMV, ‘‘empty’’ OMV at different dilutions
and used to infect LLC-MK2 cell monolayers, in comparison
with EBs treated with corresponding dilutions of pre-immune
sera. As controls, EBs were also incubated with anti-CM
rMOMP and anti-CT rMOMP antibodies. The antiserum
neutralization activity was determined by measuring the reduc-
tion of the number of inclusions generated by antibody-
opsonized EBs after correction for background inhibition
observed with pre-immune sera. The graphs present the percent
neutralization averaged from triplicate experiments, with stan-
dard deviations.
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peptides (10-residue overlap), spanning the amino acid
sequence of the mature CM HtrA form, from amino acid
17 to 497, were synthesized on a cellulose membrane and
peptide recognition profiles of the 2 sera were compared
by dot blot analysis. As shown in Fig. 5, a clear difference
was observed: while anti-CM rHtrA antibodies almost
exclusively recognized 4 adjacent peptides spanning the
HtrA sequence from amino acid 87 to 106 (included in
Region 3 in Fig. 5B), anti-CM rHtrA-OMVs antibodies
recognized a sequence that only partiallyoverlapswith the
anti-CM rHtrA target region, but interacted with 7
additional regions. Interestingly enough, the recognition
pattern of anti-CM rHtrA-OMV antibodies was highly
similar to the peptide recognition profile of a pool of sera
from mice infected with CM EBs.
Overall, the epitope mapping analysis showed that the
immunogenic profile of anti-CM rHtrA-OMV antibodies
differed from that of the antibodies induced by CM
rHtrA and mimics the epitope recognition of anti-HtrA
antibodies induced by Chlamydia experimental infection
in mice.
Discussion
The good efficacy and safety profiles of the OMV-based
licensed vaccines and our improved understanding of
OMVs’ biology, biogenesis and unique adjuvanticity
properties have stimulated the interest in OMVs as a
platform for vaccine development. OMV-based vaccine
development is moving along 2 major trajectories: vac-
cines based on OMVs from Gram-negative bacterial
pathogens andused topreventinfections by thepathogens
they derived from and vaccines based on recombinant
OMVs decorated with heterologous antigens. The latter
approach offers the possibility to design multivalent, easy-
to-producevaccineshavingbuilt-inadjuvanticity.Another
attractive aspect of the recombinant OMVs platform is
that the expression of heterologous membrane-associated
antigens, that is, proteins that require membrane interac-
tion for proper folding, can theoretically be achieved
preserving their native conformation. This would be an
important property since functional antibodies targeting
membrane protein antigens often recognize conforma-
tional epitopes.
In this work, we show that Chlamydial HtrA can be
delivered to the OMV compartment and in doing so it
folds in a conformation that elicits functional antibodies.
Our interest in Chlamydial HtrA was triggered by the
fact that Chlamydia infection induces HtrA-specific
CD4
 T cells both in humans and in mice (15). Fur-
thermore, a combination of 4 Chlamydial antigens
including HtrA elicited better protection in an experi-
mental mouse model of Chlamydia infection (15). HtrA-
mediated protection could theoretically involve the
elicitation of both cell-mediated immunity and neutraliz-
ing antibodies since HtrA is exposed on the surface of
Chlamydial EBs (24, and this work). However, as
demonstrated here, anti-rHtrA antibodies did not pre-
vent EBs from infecting epithelial cells in vitro. Since the
recombinant HtrA used for immunization was expressed
in the cytoplasm of E. coli, we thought that it could have
a conformation partially different from the one assumed
on the cell surface.
HtrA is an interesting protein from a structural
standpoint. It is a multimeric periplasmic protein with a
strong propensity to interact with phospholipids, such as
phosphatidylglycerol (PG). Since phospholipids, PG in
particular, constitute the bacterial inner membrane, it has
been proposed that HtrA interacts with the periplasmic
side of the inner membrane (19). Using a PG/DegP
proteinliposome system, Skorko-Glonek and colleagues
showed that membrane binding leads to slight changes in
E. coli HtrA multimeric secondary structure with con-
comitant decrease in thermal stability and increase in
proteolytic activity (18). More recently, Shen and collea-
gues elegantly demonstrated that, when on membranes,
DegP appears as bowl-shaped oligomeric structures
which assemble independently of the substrate. The
authors propose that this new form of DegP, which
features high proteolytic activity and low chaperone-like
activity, may play vital physiological roles in vivo (32).
On the basis of all these pieces of information, we
analyzed whether Chlamydial HtrA expressed in the E.
coli periplasm could become associated with the OMVs
and if so it could assume a conformation similar to the
one present on the surface of chlamydial EBs, thus
inducing neutralizing antibodies. Indeed, here we demon-
strated that chlamydial HtrA associates with the OMVs,
opening an interesting question on whether such associa-
tion is a general feature in Gram-negative bacteria and,
should this be the case, which might be its physio-
logical role. Indeed, our proteomic analysis indicates
that also the E. coli HtrA (DegP) is present in OMVs.
More surprisingly, our immunogold electron microscopy
analysis showed that the protein is at least partially
localized on the surface of OMVs and seems to be
organized in spherical particles that could resemble the
bowl-shaped structure proposed by Shen and colleagues
(29). Interestingly, while analyzing DegP localization in
Bordetella pertussis, Baud andcolleagues reported that the
protein is also associated with the membrane, and their
EM analysis of a high-molecular-weight fraction of
purified Bordetella DegP appeared similar to what we
observed in this work (33). Recently, Wu and colleagues
showed that CT HtrA is detected as organism-free
granules within the lumen of inclusions before being
secreted into the cytosol of infected cells (22). Based on
experimental evidences demonstrating the presence of
vesicles inside and outside the chlamydial inclusion, the
author hypothesizes that HtrA secretion occurs through a
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Citation: Journal of Extracellular Vesicles 2013, 2: 20181 - http://dx.doi.org/10.3402/jev.v2i0.20181Fig. 5. Differential epitope recognition pattern of CM rHtrA and CM rHtrA-OMV antisera. (A) Peptide arrays (96 peptides) were
prepared on a cellulose membrane by in situ synthesis of overlapping sequences of 15-residue peptides covering the amino acid sequence
of the mature CM HtrA form and tested for binding by immunoblotting with polyclonal antibodies directed against CM rHtrA-OMV
(left), CM rHtrA-OMV (centre) and CM EBs (right). Membranes incubated with serum raised against empty OMVs and run
simultaneouslygave negative staining. Numbers on the left of each blot mark the ﬁrst peptide of each row of the arrays. (B) Colour code
representation of the amino acid regions recognized by the different antisera on the mature from of the CM HtrA protein sequence. The
sequences recognized by each antiserum are highlighted according to the staining intensity of spotted peptides: red, high intensity;
orange, moderate intensity; yellow, low intensity. (C) Molecular modelling of CM HtrA multimeric forms. The 3-mer basic structure
that assembles in multiple copies to form both the bowl-shaped, lipid-associated structures and the spherical soluble structures is shown
on the left. The 4-fold symmetry bowl-like structure proposed by Shen and colleagues (29) is reported in the central panel of Fig. 5C
looking at the solvent-exposed concave face of the structure. Finally, the spherical structure of 24-mer soluble HtrA is reported in the
right-hand side of the ﬁgure. The regions recognized by anti-CM rHtrA and anti-CM rHtrA-OMV antibodies are highlighted in the 3
models maintaining the same colour code as in (B). The models were generated from PDB structure 3cs0.
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exposure of HtrA on the EB surface and indicating the
tendency of HtrA from Gram-negative bacteria to associ-
ate with OMVs, would support the idea that HtrA is
secreted by CT through a spontaneous OM blebbing and
suggest an intriguing role of OMVs in the host-interaction
mechanisms of this intracellular pathogen.
The mechanism through which DegP reaches the
surface of OMVs remains to be elucidated. OMVs’
biogenesis envisages the budding out of the OM in areas
where proteins linking the OM to peptidoglycan are
absent. The accumulation of periplasmic proteins or the
presence of curvature-inducing proteins should further
augment vesiculation (2). However, the events leading to
membrane fission still await additional studies. One
possibility is that during the fission process DegP bound
to phospholipids fuses to the OM. Alternatively, the
phospholipid-bound DegP could be released out of the
cell in proximity of membrane discontinuity occurring
during the fission process and subsequently it interacts
with the external side of the OMVs.
Whatever mechanism is involved, rHtrA-OMV has at
least 2 interesting properties from a vaccine standpoint.
First, itstimulates good levelsof HtrA-specific antibodies,
despite the fact that the amount of HtrA associated with
OMVs is relatively low (approximately 0.10.2% of total
proteins, corresponding approximately to 0.1 mgo f
protein per dose of vaccine used). This is in line with the
notion that OMVs carry most of the PAMPs present
in bacterial pathogens and so important for mounting
robust adaptive immune responses. Interestingly, such
adjuvanticity is not exerted if OMVs not carrying rHtrA
are mixed with CM rHtrA before immunization. Indeed,
HtrA-specific antibody titres were slightly reduced with
respect to the titres elicited by immunizing animals with
alum-formulated rHtrA in the absence of OMVs. The
absence of an immunostimulatory effect of ‘‘empty’’
OMV on the elicitation of anti-CM rHtrA antibodies
could be explained considering that for an adjuvant to
exert its action, adjuvant/antigen codelivery to the same
antigen presenting cell (APC) is usually required (3436).
Since the amount of total OMV proteins largely exceeds
the amount of HtrA (50 mgv s .1mg) and since mixing
recombinant HtrA to OMVs does not guarantee an
efficient antigen (HtrA)/adjuvant (OMV) codelivery to
the same APC (a situation that instead occurs with CM
rHtrA-OMV immunisation), a large fraction of the anti-
body population elicited upon immunization with CM
rHtrAOMV is expected to be directed towards the
OMVs’ proteins.
The second interesting property of CM rHtrA-OMV
is that it induces functional antibodies, as judged by
the ability to neutralize in vitro infectivity of EBs. This
property has 2 implications. First, Chlamydia HtrA is
somehow directly or indirectly involved in EB interaction
with host cells, in line with our finding that the protein is
surface exposed and second is that the conformation of
OMV-associated HtrA resembles the one present on the
surface of the EBs. Such conformation, which is likely to
be mediated by HtrA interaction with lipid membranes,
differs from the one assumed by the protein in the
absence of lipids, as it is the recombinant protein purified
from the cytoplasm of E. coli. The difference between the
2 conformations, which are both multimeric and enzy-
matically active, becomes indirectly evident by looking at
the epitope recognition profiles of antibodies induced by
immunization with CM rHtrA and CM rHtrA-OMV.
While anti-CM rHtrA antibodies mostly recognize a
region localized upstream and adjacent the proteolytic
domain, anti-CM rHtrA-OMV antibodies also bind
regions which map in the substrate-binding region (37)
and the PDZ2 domain, the latter known to be involved
in the formation of high-molecular-weight multimers
(38). This is in line with the data reported by Shen and
colleagues showing that the main differences between the
oligomeric structures of membrane-free HtrA and mem-
brane-associated HtrA occur at the intertrimer interfaces,
where the PDZ1 and PDZ2 interactions appear to be
weaker and more flexible in the bowl structure expected
to be assumed upon membrane interaction, with respect
to the spherical structure of the soluble multimeric HtrA
(32). The different antibody profile elicited by CM rHtrA
and CM rHtrA-OMV is further corroborated by our
analysis of CM HtrA molecular model made on the
crystal structures of E. coli HtrA. The modelling would
indicate that the soluble spherical multimeric forms of
CM rHtrA well expose the reactive region R3 (Fig. 5C),
while the regions specifically recognized by anti-CM
rHtrA-OMV antibodies (regions R5 and R6) are largely
buried. In contrast, when we modelled the CM HtrA
trimers in the lipid-associated, bowl-shaped structure
proposed by Shen and colleagues (in Figure 5C the 4-
fold symmetry bowl structure is shown), the R3 region
tilts towards the bounded lipid membrane, suggesting
why R3 region is less extensively recognized by anti-CM
rHtrA-OMV antibodies, while R5 and R6 regions find
themselves in the open chamber of the bowl structure,
thus getting exposed to the solvent and becoming
potentially accessible to antibody binding.
The mechanisms by which anti-CM rHtrA-OMV
antibodies reduce Chlamydia infectivity in vitro remain
to be elucidated. At least 2 possible explanations can
be proposed. First, chlamydial HtrA is part of, or in
proximity to, the component(s) recognized by the cellular
receptor(s) involved in Chlamydial cell interaction and
binding. In this case, the anti-CM rHtrA-OMVantibodies
would decorate the HtrA associated with the EB surface
much better than what the anti-CM rHtrAwould do, thus
preventing an efficient binding to the cell. Alternatively,
should the proteolytic activity of HtrA be important
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and colleagues (24), anti-CM rHtrA-OMV antibodies
would efficiently inhibit the protease activity, thus im-
pairing Chlamydia ability to infect cells. This latter
hypothesis is currently under investigation.
The combination of rHtrA with other 3 Chlamydia
antigens is protective and protection was shown to be
largely mediated by IFNg-producing CD4
 T cells (15).
It will be interesting to analyze whether the replacement
of rHtrA antigen with rHtrA-OMV further increases the
protective activity of the antigen combination. Such
increase could be mediated by the contribution of anti-
HtrA neutralizing antibodies and by the strong adjuvant
properties of OMVs.
For HtrA-OMV to become a component of a chlamy-
dial vaccine, 3 aspects have to be addressed: (a) OMV
production yield; (b) amount of HtrA in OMVs; and (c)
OMV reactogenicity. Our data indicate that approxi-
mately 2 mg/L of OMVs are produced under laboratory
conditions. We expect that such yields could be substan-
tially improved in fermentation, as recently described by
Berlanda Scorza and colleagues (39). Regarding HtrA
relative concentration in OMVs, if required this could be
increased either by modifying the promoter region and/or
translation efficiency and RNA stability or by deleting
some of the non-essential abundant proteins present in
OMVs. We have recently estimated that 10 proteins
account for approximately 50% of the total E. coli
OMV protein content, and therefore the deletion of
only few genes could be sufficient to substantially con-
centrate HtrA in OMV preparations (Grandi, personal
communication).
Finally, it is known that OMVs can be reactogenic
when injected in animals and humans and such reacto-
genicity is mostly due the presence of LPS, a component
that plays an important role in adjuvanticity but whose
concentration has to be carefully controlled. There are 3
main approaches to reduce LPS reactogenicity. First,
OMVs can be treated with mild detergent to reduce LPS
amount. Second, OMVs can be formulated with alum to
absorb LPS. Third, it can be detoxified by genetically
modifying its chemical structure. In this respect, a
number of mutations have recently been described which
substantially reduce LPS toxicity without impairing its
adjuvanticity properties (40,41).
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